• A-1210477: Advanced Workflows for MCL-1 Inhibitor in Cancer

  2026-05-25

  MCL-1 inhibitor A-1210477 drives precise, mitochondria-mediated apoptosis modeling in MCL-1-dependent cancer cells. This article details experimental workflows, troubleshooting strategies, and unique protocol enhancements, enabling researchers to harness the compound’s selectivity for mechanistic breakthroughs in apoptosis induction.

• Doxorubicin (SKU A3966): Reliable Solutions for Cancer Assay

  2026-05-24

  This article provides an evidence-based, scenario-driven guide for using Doxorubicin (SKU A3966) in cell viability and cytotoxicity assays. By addressing common laboratory challenges—from assay reproducibility to vendor selection—it demonstrates how this chemotherapeutic agent empowers biomedical researchers with validated protocols and consistent results. Explore practical strategies rooted in quantitative data and current literature.

• Vancomycin Hydrochloride: Driving Antibiotic Resistance Insi

  2026-05-23

  This article provides translational researchers with a mechanistic and strategic perspective on Vancomycin hydrochloride as a glycopeptide antibacterial agent. By integrating protocol guidance, competitive context, and emerging evidence, it explores the compound's pivotal role in resistance research, animal infection models, and next-generation antibiotic development.

• Protein A/G Magnetic Co-IP/IP Kit: Precision in Protein Comp

  2026-05-22

  The Protein A/G Magnetic Co-IP/IP Kit leverages recombinant Protein A/G magnetic beads for robust, reproducible immunoprecipitation of mammalian protein complexes. Its streamlined workflow accelerates protein-protein interaction analysis and antibody purification, empowering detailed mechanistic studies such as those targeting the BATF2-ATF3 axis in disease models.

• Rottlerin as a PKCδ Inhibitor: Bridging Cancer and Antiviral

  2026-05-22

  Explore how Rottlerin, a selective PKC inhibitor, powerfully modulates cell signaling and blocks viral entry. This article uniquely examines its dual roles in cancer biology and antiviral research, drawing from the latest scientific breakthroughs.

• Combinational Targeting of eIF4F, AKT1, and EZH2 in BRAFV600

  2026-05-21

  This study reveals that combined inhibition of the eIF4F complex, AKT1, and EZH2 overcomes resistance to targeted therapies in BRAFV600E mutant melanoma cells. The findings highlight the mechanistic interplay between translational control, kinase signaling, and epigenetic regulation, offering a rationale for multi-targeted regimens in melanoma research.

• PF-562271 HCl: Reliable FAK/Pyk2 Inhibition for Cancer Assay

  2026-05-21

  This article addresses persistent challenges in cell viability and proliferation assays by exploring how PF-562271 HCl (SKU A8345) delivers reproducible, selective inhibition of FAK/Pyk2. Drawing on scenario-based Q&A and current literature, it guides biomedical researchers in optimizing cancer research workflows and interpreting kinase inhibition data with confidence.

• Structure-Based Screening Identifies NSP15 Inhibitors in SAR

  2026-05-20

  This study applies structure-based virtual screening to identify thymopentin and oleuropein as potent inhibitors of NSP15, a SARS-CoV-2 endoribonuclease critical for viral immune evasion. The findings provide a foundation for repurposing approved molecules and developing novel antiviral strategies targeting NSP15-mediated pathogenesis.

• Etoposide (VP-16): Applied Protocols for Cancer Cell DNA Dam

  2026-05-20

  Unlock the full potential of Etoposide (VP-16) in advanced DNA damage assays and apoptosis induction workflows, leveraging insights from nanoparticle delivery innovations. This article bridges bench research with troubleshooting and protocol enhancements for cancer chemotherapy research using APExBIO’s trusted compound.

• Deferasirox Fe3+ Chelate: Redefining Iron Overload Research

  2026-05-19

  This thought-leadership article explores how Deferasirox Fe3+ chelate (Exjade) is transforming translational research in iron overload, particularly in beta-thalassemia and chronic anemia. Blending mechanistic insight—centered on mitochondrial ROS, NF-κB modulation, and myeloid differentiation—with practical protocol guidance, it offers researchers a strategic roadmap for experimental design and clinical translation. The article highlights APExBIO’s high-purity, DMSO-soluble Deferasirox Fe3+ chelate as the gold standard for advanced iron chelation research, and positions this discussion as a bridge between established literature and future innovation.

• EdU Flow Cytometry Assay Kits (Cy5): Practical Workflow Guid

  2026-05-19

  The EdU Flow Cytometry Assay Kits (Cy5) enable reliable, sensitive detection of cell proliferation by quantifying DNA synthesis during the S-phase, without requiring DNA denaturation. This assay is suitable for researchers needing robust, reproducible flow cytometry–based cell proliferation analysis, but is not intended for applications requiring live-cell tracking or real-time kinetic measurements.

• TQB3720 Induces Ferroptosis via AR/GPX4 Axis in Prostate Can

  2026-05-18

  This study identifies the second-generation androgen receptor antagonist TQB3720 as a potent inducer of ferroptosis in prostate cancer by disrupting the AR/SP1–GPX4 axis. The findings offer a mechanistic advance in prostate cancer therapy and provide a rationale for further targeting of ferroptotic pathways in oncological research.

• Scenario-Driven Best Practices with FLAG tag Peptide (DYKDDD

  2026-05-18

  This article empowers laboratory scientists to optimize recombinant protein purification and detection by addressing common workflow challenges with the FLAG tag Peptide (DYKDDDDK), SKU A6002. Drawing on validated protocols and real-world scenarios, it demonstrates how this high-purity, highly soluble peptide from APExBIO enhances reproducibility, specificity, and workflow efficiency in demanding cell-based assays.

• QNZ (EVP4593): Precision NF-κB Inhibition for Translational

  2026-05-17

  QNZ (EVP4593) is a nanomolar quinazoline derivative that enables robust NF-κB pathway modulation in both inflammation and neurodegenerative disease models. This guide details advanced workflows, troubleshooting strategies, and translational insights to help researchers achieve reproducible results using APExBIO’s QNZ (EVP4593) in complex experimental settings.

• Monomethyl Auristatin E (MMAE): Precision Antimitotic Payloa

  2026-05-16

  Monomethyl auristatin E (MMAE) is a potent antimitotic agent used as a cytotoxic payload in antibody-drug conjugates (ADCs) for targeted cancer therapy. MMAE blocks tubulin polymerization, disrupts microtubule dynamics, and achieves sub-nanomolar cytotoxicity in diverse cancer models. APExBIO’s MMAE (SKU A3631) offers high purity and reproducibility, supporting both in vitro and in vivo translational workflows.

461 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page